BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 5, 2016
View Archived Issues
Aralez to acquire U.S. rights to Toprol-XL from AstraZeneca
Read More
Morphotek signs exclusive license agreement with Eurofarma Laboratiorios
Read More
English NICE recommends Tagrisso as second-line treatment for EGFR T790M-positive NSCLC
Read More
Recursion Pharmaceuticals completes series A funding round
Read More
Therapeutic potential of targeting of PLAUR/TLR4 interaction in TP53-positive cancers
Read More
Catabasis Pharmaceuticals completes target enrollment for part B of MoveDMD trial
Read More
TAK1 is a promising new target for osteoarthritis
Read More
FDA accepts IND application for ASN-003
Read More
Daiichi Sankyo enters collaboration with AgonOx to develop immuno-oncology target
Read More
EMA grants SME designation to Dipexium Pharmaceuticals
Read More
FDA grants breakthrough therapy designation to Actemra for giant cell arteritis
Read More
New BARDA contract supports advanced development of V-920 Ebola Zaire vaccine
Read More
Ocular Therapeutix initiates first phase III trial of OTX-TP for glaucoma and ocular hypertension
Read More
Merck & Co. patents PDE2A inhibitors
Read More
Heptares Therapeutics discloses muscarinic M1 and M4 receptor agonists
Read More
Bristol-Myers Squibb describes TNF-alpha antagonists
Read More
Turing and Washington University partner on toxoplasmosis
Read More
GlaxoSmithKline presents bromodomain inhibitors
Read More
The Vanderbilt University reports mGlu2 receptor negative allosteric modulators
Read More
Altor and NantKwest sign cancer immunotherapy codevelopment agreement
Read More
twoXAR collaborates with Mount Sinai researchers in diabetic nephropathy
Read More
Bone Therapeutics reports promising data on Allob from phase IIa spinal fusion trial
Read More
Riptide Bioscience executes CRDA with NCI
Read More
Slit3 shows potential as a therapeutic target in metabolic bone diseases
Read More
Dimerix reports positive safety data for phase II trial of DMX-200
Read More
Lrp6 may be a new PTH-activated aNAC target gene
Read More
FDA grants orphan drug designation to AbbVie's atrasentan
Read More